Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 national diabetes registries.


Journal

The lancet. Diabetes & endocrinology
ISSN: 2213-8595
Titre abrégé: Lancet Diabetes Endocrinol
Pays: England
ID NLM: 101618821

Informations de publication

Date de publication:
11 2022
Historique:
received: 10 05 2022
revised: 10 08 2022
accepted: 16 08 2022
pubmed: 7 10 2022
medline: 2 11 2022
entrez: 6 10 2022
Statut: ppublish

Résumé

An increased prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in children was observed in various diabetes centres worldwide during the COVID-19 pandemic. We aimed to evaluate trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes before and during the COVID-19 pandemic, and to identify potential predictors of changes in diabetic ketoacidosis prevalence during the pandemic. For this international multicentre study, we used data from 13 national diabetes registries (Australia, Austria, Czechia, Denmark, Germany, Italy, Luxembourg, New Zealand, Norway, Slovenia, Sweden, USA [Colorado], and Wales). The study population comprised 104 290 children and adolescents aged 6 months to younger than 18 years, who were diagnosed with type 1 diabetes between Jan 1, 2006, and Dec 31, 2021. The observed diabetic ketoacidosis prevalence in 2020 and 2021 was compared to predictions based on trends over the pre-pandemic years 2006-19. Associations between changes in diabetic ketoacidosis prevalence and the severity of the COVID-19 pandemic and containment measures were examined with excess all-cause mortality in the whole population and the Stringency Index from the Oxford COVID-19 Government Response Tracker. 87 228 children and adolescents were diagnosed with type 1 diabetes between 2006 and 2019, 8209 were diagnosed in 2020, and 8853 were diagnosed in 2021. From 2006 to 2019, diabetic ketoacidosis at diagnosis of type 1 diabetes was present in 23 775 (27·3%) of 87 228 individuals and the mean annual increase in the prevalence of diabetic ketoacidosis in the total cohort from 2006 to 2019 was 1·6% (95% CI 1·3 to 1·9). The adjusted observed prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes was 39·4% (95% CI 34·0 to 45·6) in 2020 and 38·9% (33·6 to 45·0) in 2021, significantly higher than the predicted prevalence of 32·5% (27·8 to 37·9) for 2020 and 33·0% (28·3 to 38·5) for 2021 (p<0·0001 for both years). The prevalence of diabetic ketoacidosis was associated with the pandemic containment measures, with an estimated risk ratio of 1·037 (95% CI 1·024 to 1·051; p<0·0001) per ten-unit increase in the Stringency Index for 2020 and 1·028 (1·009 to 1·047; p=0·0033) for 2021, but was not significantly associated with excess all-cause mortality. During the COVID-19 pandemic, there was a marked exacerbation of the pre-existing increase in diabetic ketoacidosis prevalence at diagnosis of type 1 diabetes in children. This finding highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents. German Federal Ministry for Education and Research, German Robert Koch Institute, German Diabetes Association, German Diabetes Foundation, Slovenian Research Agency, Welsh Government, Central Denmark Region, and Swedish Association of Local Authorities and Regions.

Sections du résumé

BACKGROUND
An increased prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in children was observed in various diabetes centres worldwide during the COVID-19 pandemic. We aimed to evaluate trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes before and during the COVID-19 pandemic, and to identify potential predictors of changes in diabetic ketoacidosis prevalence during the pandemic.
METHODS
For this international multicentre study, we used data from 13 national diabetes registries (Australia, Austria, Czechia, Denmark, Germany, Italy, Luxembourg, New Zealand, Norway, Slovenia, Sweden, USA [Colorado], and Wales). The study population comprised 104 290 children and adolescents aged 6 months to younger than 18 years, who were diagnosed with type 1 diabetes between Jan 1, 2006, and Dec 31, 2021. The observed diabetic ketoacidosis prevalence in 2020 and 2021 was compared to predictions based on trends over the pre-pandemic years 2006-19. Associations between changes in diabetic ketoacidosis prevalence and the severity of the COVID-19 pandemic and containment measures were examined with excess all-cause mortality in the whole population and the Stringency Index from the Oxford COVID-19 Government Response Tracker.
FINDINGS
87 228 children and adolescents were diagnosed with type 1 diabetes between 2006 and 2019, 8209 were diagnosed in 2020, and 8853 were diagnosed in 2021. From 2006 to 2019, diabetic ketoacidosis at diagnosis of type 1 diabetes was present in 23 775 (27·3%) of 87 228 individuals and the mean annual increase in the prevalence of diabetic ketoacidosis in the total cohort from 2006 to 2019 was 1·6% (95% CI 1·3 to 1·9). The adjusted observed prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes was 39·4% (95% CI 34·0 to 45·6) in 2020 and 38·9% (33·6 to 45·0) in 2021, significantly higher than the predicted prevalence of 32·5% (27·8 to 37·9) for 2020 and 33·0% (28·3 to 38·5) for 2021 (p<0·0001 for both years). The prevalence of diabetic ketoacidosis was associated with the pandemic containment measures, with an estimated risk ratio of 1·037 (95% CI 1·024 to 1·051; p<0·0001) per ten-unit increase in the Stringency Index for 2020 and 1·028 (1·009 to 1·047; p=0·0033) for 2021, but was not significantly associated with excess all-cause mortality.
INTERPRETATION
During the COVID-19 pandemic, there was a marked exacerbation of the pre-existing increase in diabetic ketoacidosis prevalence at diagnosis of type 1 diabetes in children. This finding highlights the need for early and timely diagnosis of type 1 diabetes in children and adolescents.
FUNDING
German Federal Ministry for Education and Research, German Robert Koch Institute, German Diabetes Association, German Diabetes Foundation, Slovenian Research Agency, Welsh Government, Central Denmark Region, and Swedish Association of Local Authorities and Regions.

Identifiants

pubmed: 36202118
pii: S2213-8587(22)00246-7
doi: 10.1016/S2213-8587(22)00246-7
pmc: PMC9597608
pii:
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

786-794

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

Diabetologia. 2020 Aug;63(8):1530-1541
pubmed: 32382815
Pediatr Diabetes. 2022 Jun;23(4):433-438
pubmed: 35218124
Pediatr Diabetes. 2021 Sep;22(6):900-908
pubmed: 33978305
Pediatr Diabetes. 2018 Oct;19 Suppl 27:155-177
pubmed: 29900641
Diabetes Care. 2019 Mar;42(3):443-449
pubmed: 30573652
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Nat Hum Behav. 2021 Apr;5(4):529-538
pubmed: 33686204
Horm Res Paediatr. 2022;95(4):393-396
pubmed: 35780775
Diabetes Care. 2022 Aug 1;45(8):1762-1771
pubmed: 35043145
Pediatr Diabetes. 2022 Feb;23(1):10-18
pubmed: 34865288
JAMA. 2020 Aug 25;324(8):801-804
pubmed: 32702751
Lancet Diabetes Endocrinol. 2022 Aug;10(8):589-596
pubmed: 35803296
Pediatr Diabetes. 2021 Jun;22(4):552-557
pubmed: 33745226
Front Endocrinol (Lausanne). 2022 Mar 09;13:856958
pubmed: 35355556
Front Pediatr. 2022 Feb 14;10:820156
pubmed: 35237540
JAMA Cardiol. 2020 Oct 1;5(10):1154-1163
pubmed: 32558876
Elife. 2021 Jun 30;10:
pubmed: 34190045
JAMA Pediatr. 2022 Apr 1;176(4):414-415
pubmed: 35072727
Pediatr Diabetes. 2022 Sep;23(6):749-753
pubmed: 35366047
Diabetes Care. 2020 Nov;43(11):2768-2775
pubmed: 32962981
Diabet Med. 2021 Jan;38(1):e14417
pubmed: 33020999
J Pediatr. 2010 Mar;156(3):472-7
pubmed: 19962155
Endocrinol Metab Clin North Am. 2000 Dec;29(4):657-82
pubmed: 11149156
Nat Rev Dis Primers. 2020 May 14;6(1):40
pubmed: 32409703
Diabetes Care. 2021 Jul;44(7):1540-1546
pubmed: 33990377
ESC Heart Fail. 2021 Feb;8(1):333-343
pubmed: 33283476

Auteurs

Niels H Birkebaek (NH)

Department of Pediatrics and Adolescent Medicine and Steno Diabetes Center Aarhus, Aarhus University Hospital, Aarhus, Denmark. Electronic address: nielbirk@rm.dk.

Clemens Kamrath (C)

Division of Pediatric Endocrinology and Diabetology, Center of Child and Adolescent Medicine, Justus Liebig University, Giessen, Germany.

Julia M Grimsmann (JM)

Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany; German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.

Karin Aakesson (K)

Department of Paediatrics, County Hospital Ryhov, Jönköping, Sweden; Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.

Valentino Cherubini (V)

Department of Women's and Children's Health, Salesi Hospital, Ancona, Italy.

Klemen Dovc (K)

Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, UMC Ljubljana, University Children's Hospital, Ljubljana, Slovenia; Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.

Carine de Beaufort (C)

Department of Pediatric Diabetes and Endocrinology, Centre Hospitalier Luxembourg, Luxembourg.

Guy T Alonso (GT)

Barbara Davis Center for Diabetes, University of Colorado School of Medicine, Aurora, CO, USA.

John W Gregory (JW)

Division of Population Medicine, School of Medicine, Cardiff University, Heath Park, Cardiff, UK.

Mary White (M)

Department of Endocrinology and Diabetes, and Health Services Research Unit, The Royal Children's Hospital, Parkville, Melbourne, VIC, Australia; Diabetes Research, Murdoch Children's Research Institute, Parkville, Melbourne, VIC, Australia; Department of Paediatrics, University of Melbourne, Parkville, Melbourne, VIC, Australia.

Torild Skrivarhaug (T)

Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Zdenek Sumnik (Z)

Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czechia; University Hospital Motol, Prague, Czechia.

Craig Jefferies (C)

Starship Children's Health and University of Auckland, Auckland, New Zealand.

Thomas Hörtenhuber (T)

Department of Pediatrics and Adolescent Medicine, Kepler University Clinic, Linz, Austria.

Aveni Haynes (A)

Children's Diabetes Centre, Telethon Kids Institute, The University of Western Australia, Perth, WA, Australia.

Martin De Bock (M)

Department of Paediatrics, University of Otago, Christchurch, New Zealand.

Jannet Svensson (J)

Steno Diabetes Center Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Justin T Warner (JT)

Department of Paediatric Endocrinology and Diabetes, Children's Hospital for Wales, Cardiff, UK.

Osman Gani (O)

Division of Paediatric and Adolescent Medicine, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Rosaria Gesuita (R)

Centre of Epidemiology and Biostatistics, Polytechnic University of Marche, Ancona, Italy.

Riccardo Schiaffini (R)

Diabetes Unit, Bambino Gesù Childrens' Hospital, Rome, Italy.

Ragnar Hanas (R)

NU Hospital Group, Uddevalla, Trollhättan, Sweden; Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden.

Arleta Rewers (A)

Denver Scool of Medicine, Anschutz Medical Campus, University of Colorado, Aurora, CO, USA.

Alexander J Eckert (AJ)

Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany; German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.

Reinhard W Holl (RW)

Institute of Epidemiology and Medical Biometry, ZIBMT, Ulm University, Ulm, Germany; German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany.

Ondrej Cinek (O)

Department of Pediatrics, 2nd Faculty of Medicine, Charles University in Prague, Prague, Czechia; University Hospital Motol, Prague, Czechia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH